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D
iabetes mellitus, characterized by
accumulating glucose concentra-
tions in the blood, is a major global
public health epidemic which currently af-
fects an estimated 366million people across
the world.1 Diabetes is a result of the body's
inability to produce enough insulin (type 1)
or cells that do not respond to the insulin
that is produced (type 2). Current standard
care for type 1 diabetic patients and ad-
vanced type 2 diabetic patients requires
consistent monitoring of blood glucose
levels and subsequent insulin injections to
achieve normoglycemia.2 However, such
self-administration, known as open-loop
insulin delivery, can be painful and result
in poor compliance and glucose control.3,4
Lack of tight control of blood glucose levels
accounts for many chronic complications of
diabetes such as limb amputation, blind-
ness, and kidney failure, while hypoglyce-
mia results in risks of seizures, unconscious-
ness, brain damage, or death.5 In addition,
there are challenges to accurate monitoring
of daily glycemic ﬂuctuations in order to
intervene with the appropriate insulin
treatments.6,7
Signiﬁcant eﬀort has been focused on
developing a “closed-loop” system capable
of continuously delivering accurate levels
of insulin in response to in vivo glucose
levels.4,8 One strategy is to integrate both
a glucose-sensing moiety and a sensor-
triggered insulin releasing element within
one system.4 A semiautomated closed-loop
insulin delivery device has been created
using a continuous glucose-monitoring sen-
sor and an external insulin infusion pump.
However, challenges, such as guaranteeing
accurate signal feedback and preventing
biofouling, associated with this implantable
device still persist today.4 An alternative
approach has been to develop polymeric
biomaterials to achieve chemically con-
trolled closed-loop insulin delivery.3,4 Exam-
ple approaches have been developed by
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ABSTRACT Diabetes mellitus, a disorder of glucose regulation, is a global
burden aﬀecting 366 million people across the world. An artiﬁcial “closed-loop”
system able to mimic pancreas activity and release insulin in response to glucose
level changes has the potential to improve patient compliance and health. Herein
we develop a glucose-mediated release strategy for the self-regulated delivery of
insulin using an injectable and acid-degradable polymeric network. Formed by
electrostatic interaction between oppositely charged dextran nanoparticles loaded
with insulin and glucose-speciﬁc enzymes, the nanocomposite-based porous architecture can be dissociated and subsequently release insulin in a
hyperglycemic state through the catalytic conversion of glucose into gluconic acid. In vitro insulin release can be modulated in a pulsatile proﬁle in response
to glucose concentrations. In vivo studies validated that these formulations provided improved glucose control in type 1 diabetic mice subcutaneously
administered with a degradable nano-network. A single injection of the developed nano-network facilitated stabilization of the blood glucose levels in the
normoglycemic state (<200 mg/dL) for up to 10 days.
KEYWORDS: drug delivery . diabetes . insulin . glucose-responsive . closed-loop . nano-network
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integration of glucose-sensing moieties such as glu-
cose oxidase (GOx),913 lectin (ConA),14,15 and syn-
thetic phenylboronic acid (PBA).1620
GOx is an enzyme which catalyzes the conversion of
glucose to gluconic acid in the presence of oxygen
shown in the following reaction:21
glucoseþO2þH2O sfGOx gluconic acidþH2O2
Previous glucose-responsive systems with GOx typi-
cally entrap or immobilize the enzyme within bioma-
terials, causing a local decrease in pH with increasing
glucose concentrations.13,22,23 As a result, materials can
be designed to adapt to subtle pH changes which alter
the material properties of the device and allow for
tailorable release of loaded insulin in response to
increasing blood glucose concentrations. On the basis
of this strategy, a number of bulk hydrogel matrices or
membranes have been developed.3,4 However, bulk
hydrogel systems exhibit slow response to changes
in glucose concentration due to mass transport
limitations,4 while GOx-containing membranes suﬀer
from low mechanical strength, which can result in
premature insulin leakage.4 In this report, we develop
an injectable polymeric nanoparticle-cross-linked net-
work (designated nano-network) capable of glucose-
mediated insulin delivery. Using chemically modiﬁed
dextran (designated m-dextran) as an acid-degradable
and biocompatible matrix material, we have demon-
strated that the resulting nano-network can be utilized
for glucose-regulated insulin delivery.
RESULTS AND DISCUSSION
A schematic of the nano-network is shown in Figure 1.
Oppositely charged degradable nanoparticles inter-
act and self-assemble through electrostatic forces24
to create a cohesive gel-like network. The produced
gel network forms a stable three-dimensional, porous
structure, which yields an increased surface area to
volume ratio for maximum interaction between glu-
cose and GOx (Figure 2b). Materials of this design
have been reported to enable the release of payloads
with near zero-order kinetics.25 Additionally, the nano-
network produces shear-thinning behavior due to the
disruption of particleparticle interactions as the ap-
plied shear force is increased. Once the external force is
withdrawn, the strong cohesive property is recovered,
which allows for convenient molding and injection
(Figure 2d).
The nanoparticles used to form this nano-network
were prepared by a double emulsion (water-in-oil-in-
water)-based solvent evaporation/extraction method
and comprised four components: acid-degradable
polymeric matrix, polyelectrolyte-based surface coat-
ings, encapsulated glucose-speciﬁc enzymes (GOx and
Figure 1. Schematic of the glucose-responsive nano-network. (a) Nanoparticles (NPs) encapsulating insulin and glucose-
speciﬁc enzymes (GOx, glucose oxidase; CAT, catalase) are made of acidic sensitive acetal-modiﬁed dextran (b) and coated
with chitosan and alginate, respectively. (c) Nano-network (NN) is formed by mixing oppositely charged nanoparticles
together and eﬃciently degrades to release insulin upon the catalytic generation of gluconic acid under hyperglycemic
conditions. (d) Schematic of glucose-mediated insulin delivery for type 1 diabetes treatment using the STZ-induced diabetic
mice model.
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catalase (CAT)), and recombinant insulin. Dextran was
selected due to its biocompatibility, biodegradability,
and ease of modiﬁcation.26 To enable water-soluble
dextran to encapsulate hydrophilic payloads, hydroxyls
of dextran were modiﬁed with pendant acetals (desig-
nated m-dextran) via an acid-catalyzed reaction with
ethoxypropene (Supporting Information Figures S1S3).27
The m-dextran is soluble in organic solvents typically used
for emulsion techniques, such as dichloromethane and
acetone. More importantly, the incorporation of ethoxy-
propene provides a pH-sensitive element, which is
expected to hydrolyze under mildly acidic aqueous
conditions and thus unveiling the natural hydroxyl
groups of dextran (Supporting Information Figure S1).
The complete hydrolysis of m-dextran results in
regeneration of water-soluble native dextran together
with ethanol and acetone, which show insigniﬁcant
toxicity in small quantities (Supporting Information
Figure S4). The enzyme GOx is the glucose-responsive
factor for generating pH stimulus, while the CAT is
applied to oﬀer oxygen (O2) to assist GOx's catalysis
and consume undesired hydrogen peroxide (H2O2)
produced by the reaction (Supporting Information
Figure S5), which maybe toxic in vivo and deactivates
GOx.23,28 Theweight ratio of GOx to CATwas optimized
as 4:1 by analyzing the catalytic capability of enzyme
mixtures at diﬀerent concentrations (Figure S5). The
ﬁnal weight ratio of m-dextran/insulin/enzymes for
preparation of glucose-responsive particles was opti-
mized and determined as 87/13/1.3, based on the
loading eﬃciency of insulin as well as response speed.
In order to obtain oppositely charged nanoparticles,
chitosan and alginate, two polysaccharides that are
used in humans,29,30 were employed as surface modi-
ﬁers to coat dextran nanoparticles. Both chitosan and
alginate were exploited to introduce both a positive
and negative surface charge, respectively, on dextran
nanoparticles. Utilizing a double emulsion procedure,
two types of dextran particles were prepared sepa-
rately with an insulin loading capacity of 7.9( 0.8 wt %
for the chitosan-coated particles and 11.4 ( 0.1 wt %
for the alginate-coated particles (Supporting Informa-
tion Table S1). As shown in the scanning electron
microscopy (SEM) images in Figure 2a, both chitosan-
and alginate-coated nanoparticles have nearly mono-
disperse particle sizes. The average hydrodynamic
particle sizes determined by dynamic light scattering
(DLS) for chitosan-coated and alginate-coated particles
were 340 and 293 nm, respectively (Supporting Infor-
mation Figure S6). The zeta-potentials for both parti-
cles were 10.6( 1.9mV (chitosan-coated) and11.5(
1.7 mV (alginate-coated) (Supporting Information
Figure 2. Characterization of the glucose-responsive nano-network. SEM images of nanoparticles (NPs) coated with chitosan
and alginate (a) and formed nano-network (b). Inset is a gel-like nano-network adhered to the bottom of an inverted vial. (c)
Laser scanning confocal microscopy image of the nano-network consisting of chitosan-coated NPs (encapsulated with FITC-
stained insulin) and alginate-coated nanoparticles (encapsulated with rhodamine-stained insulin). (d) Viscosity and shear-
thinning behaviors of the nano-network compared with pure nanoparticles. Inset shows that the collected nano-network is
injectable with suﬃcient cohesiveness through a conventional syringe.
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Table S2). The uniform and small size of these nano-
particles provided the cohesive strength, while the
opposite zeta-potentials promoted tight particle pack-
ing as a result of the electrostatic interaction.
The cohesive nano-network loaded with both en-
zymes and insulin (designatedNN(EþI)) was created by
mixing the oppositely charged dextran nanoparticle
solutions. The SEM image in Figure 2b illustrates that
nanoparticles were joined together to form a bulk
porous structure composed of a 3D network with
microchannels. The formation of domains consist-
ing of tightly packed agglomerates suggests that
the cohesive nature of the nano-network resulted from
an equilibrium of interparticle attractions (agglom-
erates) and repulsions (pores). To further validate the
interaction between oppositely charged particles,
insulin conjugated with two diﬀerent ﬂuorescent
dyes was encapsulated into nanoparticles coated with
chitosan and alginate. As demonstrated in Figure 2c,
the 3D laser scanning confocal microscopy (LSCM)
indicates that particles in the resulting network were
compacted without noticeablemobility. To investigate
the injectability of the nano-network, the viscosities
of each nanoparticle formulation and resulting nano-
networkwith the same solid contentweremeasured as
a function of shear rate (Figure 2d). The initial viscosity
of the nano-network at low shear rates compared to
pure nanoparticles conﬁrmed the formation of attrac-
tive electrostatic interaction and compact nanoparticle
packing. The cohesive forces were reduced at high
shear rate, resulting in the low viscosities that allow for
convenient injection of the nano-network through
syringes (Figure 2d).
To examine the glucose-responsive dissociation of
the nano-network, gels were collected in microcentri-
fuge tubes and incubated with PBS solutions in the
absence or presence of glucose, both at a hyperglycemic
level (400 mg dL1) and a normal level (100 mg dL1).
The nano-network material exposed to the hypergly-
cemic solution gradually dissociated over time, as
shown in Figure 3a. After 8 h, the incubated solution
became transparent due to the thorough hydrolysis of
the modiﬁed dextran into native dextran. Meanwhile,
the recorded pH values of incubating solutions sub-
stantiated that the degradation of the network corre-
lated to a decrease of the solution pH from 7.4 to
4.2, conﬁrming the enzymatic conversion of glucose to
gluconic acid. In contrast, both of the control samples
(no glucose and 100 mg dL1 glucose) did not display
observable dissociation over the 8 h time course,
consistent with lack of change in the solution pH
(Figure 3b). Additionally, we observed that the viscosity
of the nano-network at low shear rates steadily de-
creased when exposed to hyperglycemic conditions
(Supporting Information Figure S7), as a result of
decreasing cohesive forces due to the chang-
ing charges of polyelectrolytes as the pH decreases.
The overall conformational structure of released insulin
Figure 3. Glucose-responsive degradation of nano-network and insulin release. (a) Pictures of the nano-network incubated in
diﬀerent glucose concentrations in 1 PBS solution: 0, 100, and 400 mg/dL at 37 C over time. (b) Relevant pH changes in
diﬀerent incubation solutions with nano-networks. (c) CD spectra of insulin solution and insulin released from the nano-
network incubated with 400 mg/dL glucose at 37 C for 8 h. (d) In vitro accumulated insulin release of the nano-network in
diﬀerent glucose concentrations at 37 C. (e) Self-regulated proﬁle of the nano-network presents the rate of insulin release as
a function of glucose concentration. Data points represent mean ( SD (n = 2) in (a), (d), and (e).
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from the nano-network was maintained to that of
native insulin demonstrated by the circular dichroism
(CD) spectrum in Figure 3c.
We next assessed insulin release kinetics in response
to varying glucose levels. Accumulated insulin release
studies were performed and conﬁrmed that faster
insulin release was achieved from the nano-networks
under a hyperglycemic environment, as plotted in
Figure 3d. In contrast, limited insulin release from the
nano-networks was observedwithin 15 h of incubation
at the normal glucose level and glucose-free PBS
buﬀer. These results are also consistent with the
above-mentioned dissociation response. Meanwhile,
the solubility of insulin is increased under an acidic
environment, which further enhances the insulin re-
lease rate.22 Furthermore, the insulin release proﬁle of
nano-networks presented a pulsatile pattern when the
glucose concentration was cyclically varied between
the normal and hyperglycemic levels every 2 h for
several repetitions, as shown in Figure 3e. The nano-
network responded to changes of glucose levels, and a
maximum 3.6-fold increase in the insulin release rate
was obtained when the glucose level was switched to
the hyperglycemic state. Moreover, the release rates at
both hyperglycemic and normoglycemic levels stably
increased to a maximum point and then gradually
decreased. The “acceleration period” of the release
rate can be attributed to the progressively attenuated
cohesive force and dissociated structure of the net-
work. Collectively, these results point to the degrada-
tion of the nano-network and the subsequent insulin
release is a glucose-mediated and pH-dependent pro-
cess. Like a smart valve system, the insulin release
through the nano-network is facilitated at a high
glucose level and inhibited at a low glucose level.
To examine the eﬃcacy of the insulin-loaded nano-
network for diabetes treatment, streptozotocin (STZ)-
induced diabetic mice31 were subcutaneously injected
with PBS solution, human recombinant insulin solu-
tion, nano-network loaded with insulin and enzymes
(NN(EþI)), nano-network loaded with insulin only
(NN(I)), and nano-network loaded with enzymes only
(NN(E)). The blood glucose (BG) levels of administrated
mice in each group were then monitored over time. As
shown in the plots in Figure 4a and Figure S8
(Supporting Information), the BG levels of diabetic
mice treated with one injection of NN-EI were stably
maintained in the normoglycemia (<200mg/dL) range
for up to 10 days without peaks of hyperglycemic or
hypoglycemic states. For some of the treatedmice, the
BG levels were maintained in the normoglycemic
range for over 2 weeks, as shown in Figure 4b.
Figure 4. In vivo studies of the nano-network for type 1 diabetes treatment. Blood glucose levels (a) and plasma human
insulin concentration (c) in STZ-induced C57B6 diabetic mice after subcutaneous injection with 1 PBS, nano-network
encapsulated insulin and enzymes (NN(EþI)), nano-network encapsulated insulin only (NN(I)), nano-network encapsulated
with enzymes only (NN(E)), or pure insulin solution. (b) Changes of the mice number in diﬀerent groups within the
normoglycemic range (<200mg/dL) over the administration time. (d) Glycated albuminpercentages ofmice treatedwith PBS,
NN(EþI), NN(I), NN(E), and insulin solution. Student's t-test: *p < 0.05, ***p < 0.001. Data points represent mean( SD (n = 8).
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The average BG levels of the NN(EþI) group gradually
increased due to a decrease in the insulin content or
loss of bioactivity of encapsulated insulin but were still
signiﬁcantly lower than the original BG level for up to
3weeks. Correspondingly, the plasma human insulin in
mice injected with NN(EþI) can be detected over the
3 week time course (Figure 4c).
The rapid decrease in BG levels in the ﬁrst 12 h
(Figure 4a and Figure S8) is likely due to the initial burst
of the insulin released in the solution part or adhered
on the surface of the nano-network. However, the
subsequent release of the remaining insulin encapsu-
lated in nanoparticles, mediated by enzymatic cataly-
sis, took place more slowly (Figure 4a). In contrast,
the BG levels of mice treated with NN(I) maintained
BG levels within the normal range for 2 days before
returning to the hyperglycemic state. Meanwhile
BG levels of mice injected with insulin solution
increased to the hyperglycemic range on the sec-
ond day after administration. In the absence of
enzymes, NN(I) cannot undergo an acidic degrada-
tion event to eﬀectively release insulin, and thus the
BG levels of administrated mice were notably high-
er than those treated with NN(EþI). Without a load-
ing matrix, pure insulin was quickly cleared and
resulted in a rapid decrease in plasma insulin
concentration on the next day of administration
(Figure 4a).
To investigate the possible eﬀect of the catalytic
consumption of glucose on the decrease of the BG
levels, we also treated diabetic mice with NN(E). How-
ever, the conversion of glucose through enzymes did
not show a detectable eﬀect in lowering BG levels
(Figure 4a). The glucose responsiveness was tested
in vivo by an intravenous glucose tolerance test at
6 day post-injection (Supporting Information). Mice
treated with NN(EþI) showed a rapid increase in BG
levels upon glucose injection followed by a slightly
delayed decrease to ﬁnally reach normal BG levels at
80min in comparisonwith healthy animals (Supporting
Information Figure S9). We also tested the glycated
albumin level in serum, a medium term (23 weeks)
indicator of diabetic control.32 As shown in Figure 4d,
the glycated albumin ratio (glycated albumin/total
albumin) was prominently decreased 1.6-fold 2 weeks
after administration with NN(EþI). In addition, after a
4 week post-administration period, the group treated
with NN(EþI) gained higher body condition scores
compared with control groups. Taken together, sus-
tained insulin release from the degradable insulin-
loaded nano-network and the pharmacological dura-
tion of insulin activity have been observed.
To assess the biocompatibility of the nano-network,
the cytotoxicity of nanoparticles coated with chitosan
or alginate and their degradation products toward
HeLa cells was evaluated at various concentrations
ranging from 0.05 to 1.2 mg/mL. For all concentrations
studied, m-dextran-based nanoparticles and relevant
degradation products did not show signiﬁcant de-
crease of cell viability (Supporting Information Figure
S4). To further investigate in vivo biocompatibility and
degradability of the nano-network, the sizes of skin
protrusion due to the subcutaneous injection were
monitored over time. As shown in Figure 5a, the
average lump sizes in the injection sites of mice
treated with NN(EþI) steadily decreased, suggesting
Figure 5. In vivo biocompatibility analysis. (a) Changes of lump sizes in the injection sites of STZ-induced C57B6 diabeticmice
treated with NN(EþI) and NN(I) over time. (b) Pictures of mice dorsum and relevant skins (c) treated with subcutaneous
injection of NN(EþI) or NN(I) after 4weeks. Scale bars: 1 cm for (b) and 2mm for (c). (d) H&E stained sections of subcutaneously
injected NN(EþI) or NN(I) with surrounding tissues after 2 and 4 weeks, respectively. The regions of skin muscles, fat tissues,
and nano-networks are indicated by M, F, and NN, respectively. Scale bar: 200 μm.
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glucose-mediated degradation was substantially trig-
gered. No signiﬁcant skin protrusion can be found after
4 weeks (Figure 5b,c). However, for mice treated with
NN(I), the lump sizes did not obviously decrease, even
after 4 weeks. Figure 5d represents the histological
response of the injected nano-network. During the ﬁrst
2weeks, inﬂammatory cells, such aspolymorphonuclear
cells (PMN) and macrophages, were found to have
inﬁltrated into both NN(EþI) and NN(I), where the
nano-network region was avascular and acellular, and
a ﬁbrin network separated the nano-network from
the muscle region. This inﬂammatory reaction can
be attributed to the acute inﬂammation which often
occurs when biomaterials are subcutaneously im-
planted. After 4 weeks, the NN(EþI) had completely
degraded and the aﬀected region was covered with
connective tissue. However, a noticeable inﬂammatory
region can still be observed in the samples admini-
strated with NN(I).
CONCLUSION
In conclusion, we report a new platform for glucose-
mediated delivery of insulin through an injectable
nano-network. Consisting of oppositely charged dex-
tran nanoparticles encapsulating insulin and glucose-
speciﬁc enzymes, the gel-like 3D scaﬀold can be eﬀec-
tively dissociated to release insulin in a hyperglycemic
condition, where the catalytic conversion of glucose into
gluconic acid and the subsequent degradation of the
polymeric matrix are facilitated. This formulation design
provides a potential delivery strategy for both self-regu-
lated and long-term diabetes management.
METHODS
Materials. All chemicals were purchased from Sigma-Aldrich
unless otherwise specified and were used as received. Human
recombinant insulin (Zn salt, 27.5 IU/mg) was purchased
from Invitrogen. The deionized water was prepared by a
Millipore NanoPure purification system (resistivity higher than
18.2 MΩ 3 cm
1).
Preparation of m-Dextran. Briefly,1.0gofdextran (Mn∼911kDa)
was added to a flame-dried round-bottom flask and purged
with nitrogen. Ten milliliters of anhydrous dimethyl sulfoxide
was added to the flask and stirred until complete dissolution of
the dextran. Pyridinium p-toluenesulfonate (PPTS, 15.6 mg,
0.062mmol) was added to the solution followed by the addition
of 2-ethoxypropene (4.16 mL, 37 mmol). The reaction mixture
was purged with nitrogen briefly and then sealed with parafilm
to prevent reactant evaporation. The reaction was stirred at
room temperature for 30 min, resulting in m-dextran. At that
point, the reaction was quenched by the addition of 1 mL of
triethylamine. The mixture was then precipitated and washed
three times in basic water (pH ∼8) to prevent undesired
degradation and collected by centrifugation (8000 rpm,
15 min). The product was lyophilized to remove residual water
and resulted in a white solid. IR (KBr, cm1): 3485, 2971, 2862,
1471, 1374, 1246, 1203, 1047, 806, 746, 549. 1H NMR (400 MHz,
CDCl3): δ 5.21 (br, 1H), 4.87 (br, 1H), 4.103.70 (br, 12H), 3.46 (br,
4H), 1.30 (br, 16H), 1.11 (br, 8H).
Preparation of Glucose-Responsive Nanoparticles and Nano-Network.
Dextran nanoparticles were prepared by an improved double
emulsion (water-in-oil-in-water) solvent evaporation/extraction
method. Briefly, 5.8 mL of organic phase (dichloromethane
(DCM)) containing 240 mg of m-dextran was emulsified with
0.5 mL of aqueous phase containing 35 mg of human recombi-
nant insulin (Invitrogen, USA) only or together with 3.5 mg of
enzymes (weight ratio of glucose oxidase to catalase 4:1) by
sonication for 45 cycles (1 s each with a duty cycle of 60%).
Thereafter, the primary emulsion was immediately poured into
25 mL of the chitosan or alginate aqueous solution (1%) and
sonicated for 45 cycles. The double emulsion was subsequently
transferred into 150 mL of chitosan (Mn = 612 kDa; degree of
deacetylation = 96.1%) or alginate (Mv = 1.6  105) aqueous
solution (0.2%). The mixed suspension was stirred at room
temperature to eliminate DCM by evaporation. After 2 h, the
resulting nanoparticles were cleaned and collected by repeat-
ing a procedure of centrifuging at 10 000 rpmand resuspending
in distilled water three times. The product was dried by lyophi-
lization and stored at 4 C. To obtain nano-network gels,
chitosan- or alginate-coated nanoparticles were separately dis-
persed in deionizedwater (w/v = 20%) andmixed together (w/w=
1/1) in a bath sonitator for 2 min. The prepared nano-network gel
was collected by centrifuging at 3000 rpm for 3 min and stored
at 4 C. The loading capacity (LC) and encapsulation efficiency
(EE) of insulin-encapsulated nanoparticles were determined by
measuring the amount of non-encapsulated insulin through
BCA (bicinchoninic acid) protein assay and using insulin-free
particles as basic correction. LC and EE were calculated as LC =
(A  B)/C, EE = (A  B)/A, where A was expected encapsulated
amount of insulin, B was the free amount of insulin in the
collection solution, and C was the total weight of the particles.
In Vitro Release Studies. After preparation of the nano-
network, various solutions (PBS, 100 or 400 mg dL1 glucose,
500 μL) were added to each tube and incubated at 37 C on an
orbital shaker to evaluate the release of insulin. At predeter-
mined time points, the sample was centrifuged (8000 rpm,
30 s) and 12 μL of the supernatant was removed for analysis.
Twelve microliters of fresh solution was then added to the
tube to maintain a constant volume and placed back within
the incubator. Total insulin content was measured using a
Coomassie Plus protein assay. The absorbance of the well was
detected at 595 nm, and the concentration was interpolated
from an insulin standard curve and a calibration curve using the
nano-network with enzymes only. To evaluate the material's
ability to adapt to cyclical changes in glucose levels, each nano-
network sample was first incubated in 400 mg dL1 glucose
(500 μL) for 2 h at 37 C. At that point, the sample was
centrifuged (8000 rpm, 30 s) and all of the supernatant was
recovered. The sample was washed twice with PBS and then
incubated in 100 mg dL1 glucose (500 μL) for another 2 h. This
cycle was repeated numerous times. Similarly, insulin concen-
tration was determined using the Coomassie Plus protein assay.
In Vivo Studies Using STZ-Induced Diabetic Mice. The efficacy of the
insulin-loaded nano-network for diabetes treatment was eval-
uated in vivo by assessment of glycemia in STZ-induced adult
diabetic mice (male C57B6, Jackson Lab, USA). Mice were cared
for under supervision of MIT's Division of Comparative Medicine
and in compliance with NIT's Principles of Laboratory Animal
Care. The blood glucose levels of micewere continuously tested
for 2 days before administration by collecting blood (∼3 μL)
from the tail vein and measuring using the Clarity GL2Plus
glucose monitor (VWR, USA). Eight diabetic mice were selected
for each group administered with PBS solution, insulin solution,
nano-network loaded with human recombinant insulin and
enzymes, nano-network loaded with insulin only, or nano-
network with enzyme only. One hundred fifty microliters of
the aqueous solution or nano-network was injected using a 1 cc
syringe with a 19 gauge needle into the subcutaneous dorsum
of mice (insulin dose = 60 mg/kg) that had been anesthetized
with 1% isoflurane. The glucose level of each mouse was
monitored over time (every 30 min or 2 h for the first 12 h in
the day of administration and once per day in the morning for
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following days). To measure in vivo insulin concentration, blood
samples (25 μL) were drawn from the tail vein of mice and
collected into Sarstedt serum gel microtubes. Serum samples
(5 μL) were stored frozen at20 C until assayed. Plasma insulin
concentrations were determined using the human insulin ELISA
kit (Calbiotech, USA). To quantitatively determine ratios of
glycated albumin over total albumin concentration, collected
serum samples (7 μL) were analyzed 1 day before administra-
tion and 2 weeks after administration using themouse glycated
albumin kit (Crystal Chem, USA).
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